



## ERFA Canada acquires 25 brands from Pfizer

ERFA Canada undertook the distribution and supply of medical information on 25 brands (56 SKUs), recently acquired from Pfizer Canada. The 19 currently marketed brands are Adrenalin, Amsa PD, Atarax Syrup, Celontin, Cerebyx, Chloromycetin, Cholelyl Elixir and Expectorant, Colymycin, Humatin, Ketalar, Lithane, Mandelamine, Nardil, Navane, Pro-can SR, Sinequan, Thyroid and Zarontin.

The acquisition of these valuable pharmaceu-

ticals ensures that Canadian physicians can continue prescribing proven, trusted medications to their patients.

ERFA Canada offers a wide range of products and services, including pharmaceuticals, medical devices, biotech research antibodies and test kits, e-business and web hosting services.

ERFA Canada's mission is to maintain the availability of proven pharmaceutical products that would otherwise be taken off the market due to mergers or the pruning of product portfolios. ERFA Canada achieves this by in-licensing, acquiring or providing contract manufacturing for these products.

## Pfizer establishes new CV research awards program

Pfizer Canada is proud to introduce the Pfizer Cardiovascular Research Awards program to promote partnerships for better cardiovascular care in Canada. The Awards program, announced recently at the Canadian Cardiovascular Congress, will support a variety of initiatives, from traditional clinical trials to smaller, often under-represented projects in Canadian research. All proposals will be reviewed by an independent expert review committee that has been established to evaluate and grant the Awards, chaired by Dr. Jean-Claude Tardif, Director, Research Centre, Montreal Heart

Institute, Associate Professor of Medicine, Université de Montréal and recipient of the Pfizer-Canadian Institutes of Health Research Chair of Atherosclerosis.

"Canada has a long history and commitment to cardiovascular research," says Dr. Tardif. "It is an honour to be part of such a prestigious and valuable program. In order to advance our understanding of the prevention and treatment of cardiovascular disease, it is important for new researchers, as well as established experts, to have support for research projects and initiatives. And, ultimately, it is the Canadian public that will benefit from this partnership for research and knowledge. I look forward to working with Pfizer Canada on this innovative project."



**Looking for a Supplier? Need a Specialized Service?  
Interested in Industry News & Information?**

Find it all online at:

# Pharma411.ca

**The Premiere Online Directory & Resource Site  
for the Canadian Pharmaceutical Industry**

Medzyme